Dr Reddys Drug Patent Portfolio
Dr Reddys owns 1 orange book drug protected by 2 US patents Given below is the list of Dr Reddys's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10993952 | Stable ready to use cyclophosphamide liquid formulations | 15 Feb, 2036 | Active |
| US12329767 | 15 Feb, 2036 | Active |
Latest Legal Activities on Dr Reddys's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Dr Reddys.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 May, 2024 | US10849916 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 May, 2024 | US10993952 (Litigated) |
|
Recordation of Patent Grant Mailed
Critical
| 12 Jul, 2022 | US11382923 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Jul, 2022 | US11382923 |
|
Email Notification
Critical
| 23 Jun, 2022 | US11382923 |
|
Issue Notification Mailed
Critical
| 22 Jun, 2022 | US11382923 |
| Dispatch to FDC | 08 Jun, 2022 | US11382923 |
|
Application Is Considered Ready for Issue
Critical
| 08 Jun, 2022 | US11382923 |
|
Issue Fee Payment Received
Critical
| 06 Jun, 2022 | US11382923 |
|
Issue Fee Payment Verified
Critical
| 06 Jun, 2022 | US11382923 |
| Letter Accepting Correction of Inventorship Under Rule 1.48 | 06 May, 2022 | US11382923 |
|
Email Notification
Critical
| 06 May, 2022 | US11382923 |
| Filing Receipt - Updated | 06 May, 2022 | US11382923 |
| Miscellaneous Incoming Letter | 03 May, 2022 | US11382923 |
|
Email Notification
Critical
| 25 Apr, 2022 | US11382923 |
Dr Reddys's Family Patents
Recent FDA approvals and tentative approvals for Dr Reddys
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Innovator drugs
Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Bendamustine Hydrochloride |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 5 - New Formulation or New Manufacturer | 12 Nov, 2021 |
| Pemetrexed For Injection |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 5 - New Formulation or New Manufacturer | 14 May, 2020 |
| Zenavod |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 5 - New Formulation or New Manufacturer | 27 Jan, 2016 |
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Carbidopa And Levodopa |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 13 Jun, 2025 |
| Siponimod |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 05 Jun, 2025 |
| Sitagliptin Phosphate |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 12 May, 2025 |
Dr Reddys Drug List
Given below is the complete list of Dr Reddys's drugs and the patents protecting them.
1. Cyclophosphamide
Cyclophosphamide is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10993952 | Stable ready to use cyclophosphamide liquid formulations |
15 Feb, 2036
(10 years from now)
| Active |
| US12329767 |
15 Feb, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cyclophosphamide's drug page